Visual outcomes of branch retinal artery occlusions effected by early detection

Article

Visual outcomes in patients who have experienced branch retinal artery occlusions are predicated by the level of vision at the time of presentation.

"The good news for patients with BRAO and a visual acuity of 20/40 or better is that they are likely to retain that good vision," said Peter Gehlbach, MD, PhD, associate professor of vitreoretinal surgery in the Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine.

BRVO is even more common than blockage of a branch retinal artery.

To illustrate these conclusions, Dr. Gehlbach presented a few cases to audience members at the third annual Evidence Based Care in Myopia Control, Retina, and Vision Enhancement meeting of The Wilmer Eye Institute, held in conjunction with the Maryland Optometric Association.

Presentation and prognosis

Patients with BRAO will typically present with acute, unilateral, painless, partial visual loss, with visual field defects that can be central or sectoral, Dr. Gehlbach said. These patients may even be asymptomatic. Risk factors for BRAO include smoking, hypertension, hypercholesterolemia, diabetes, coronary artery disease, and a history of stroke or transient ischemic attack.

Visual prognosis after BRAO seems to be correlated with presenting visual acuity. Eyes with an initial acuity of 20/40 or better usually remained at 20/40 or better, according to a study by Mason et al.1 In the same study, however, patients with a visual acuity of 20/100 or worse generally did not show significant improvement in vision, also supporting prior studies in this area.

BRAO and heart disease

To illustrate in application, Dr. Gehlbach related the case of a 57-year-old African American male who presented with sudden onset of a blurred area in the right eye. This patient was hypertensive and smoked. At presentation, his vision was 20/30. Fundus examination and fluorescein angiography confirmed BRAO.

The patient was referred to his internist for cardiovascular evaluation and management of cardiovascular risk factors. The internist called to inquire as to the association of BRAO and heart disease, and to determine if the patient should expect further loss of vision. Following discussion, the internist fully evaluated the patient and discovered significant cardiovascular disease. Antihypertensive therapy was instituted.

The patient was relieved to learn that, while not likely to clear, his vision loss was likely to remain stable. He volunteered that he had quit smoking after learning of the potential association between smoking and his vision.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Presenters from the Collaborative Care Symposium 2025 give their key takeaways from their presentations.
Erin Tomiyama, OD, PhD, FAAO, offers actionable advice for myopia management and perspective for practitioners ready to refine their approach.
Extended lotilaner 0.25% therapy shows meibomian gland benefits
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Carolyn Majcher, OD, FAAO, details a Collaborative Care Symposium 2025 presentation given with Prethy Rao, MD.
Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.
Lori Wright, JD, sat down to talk about a presentation at Collaborative Care Symposium about the risk under federal statutes and how to minimize that risk as an optometrist or an ophthalmic practice.
Rachelle Lin, OD, MS, FAAO, on collaborating more effectively on neovascular retinal cases
Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.
Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.
© 2025 MJH Life Sciences

All rights reserved.